Wolters Kluwer Health is the professional’s first choice for knowledge-based information services and decision-support tools for the pharmaceutical, biotechnology and life science industries.
Wolters Kluwer Health is the professional's first choice for knowledge-based information services and decision-support tools for the pharmaceutical, biotechnology and life science industries. We provide unparalleled intelligence from pre-clinical to post-market surveillance marketed under the industry's leading information brands, Adis, IFI Patent Intelligence and Lippincott Williams & Wilkins.
Adis and Lippincott Williams & Wilkins brands offer a diverse collection of more than 300 society-affiliated and proprietary journals and newsletters that are written, edited and peer reviewed by the world's most respected professionals.
Lippincott Williams & Wilkins is backed by a reputation for medical publishing that spans more than 100 years and offers the gold standard in medical textbooks that are written by some of the most prestigious authors in the world.
Adis is responsible for two premier business intelligence databases, R&D Insight and Clinical Trials Insight, which provide information and interpretation to our clients throughout the pharmaceutical product lifecycle.
Wolters Kluwer Health is a unit of WoltersKluwer nv, a leading multinational publisher and information services company with annual revenues (2004) of €3.2 billion and employing approximately 20,000 people worldwide.
For more information please visit http://www.wkhealth.com/ps.htm
For further information on Wolters Kluwer Health products and services, please contact your local office
Chester, United Kingdom:
Tel: +44 1829 772 738
Fax: +44 1829 770 330
Madrid, Spain:
Tel: +34 91 555 4062
Fax: +34 91 555 7689
Munich, Germany
Tel: +49 89 36007 3512
Fax: +49 89 36007 3514
Milan, Italy
Tel: +39 02 423 4562
Fax: +39 02 422 1200
Paris, France
Tel: +33 1 56 99 9700
Fax: + 33 1 56 99 9710
Yardley, PA, USA
Tel: +1 267 757 3400
Fax: +1 267 757 3490
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.